Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response.
Smith C, Lee V, Schuessler A, Beagley L, Rehan S, Tsang J, Li V, Tiu R, Smith D, Neller MA, Matthews KK, Gostick E, Price DA, Burrows J, Boyle GM, Chua D, Panizza B, Porceddu SV, Nicholls J, Kwong D, Khanna R. Smith C, et al. Among authors: tiu r. Oncoimmunology. 2017 Jan 4;6(2):e1273311. doi: 10.1080/2162402X.2016.1273311. eCollection 2017. Oncoimmunology. 2017. PMID: 28344888 Free PMC article.
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.
Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Recher C, Yoon SS, Maeda Y, Hosono N, Onozawa M, Kato T, Kim HJ, Hasabou N, Nuthethi R, Tiu R, Levis MJ. Perl AE, et al. Among authors: tiu r. Transplant Cell Ther. 2023 Apr;29(4):265.e1-265.e10. doi: 10.1016/j.jtct.2022.12.006. Epub 2022 Dec 13. Transplant Cell Ther. 2023. PMID: 36526260 Free PMC article. Clinical Trial.
Tracheotomy care simulation training program for inpatient providers.
Tiu RA, Meyer TK, Mayerhoff RM, Ray JC, Kritek PA, Merati AL, Sardesai MG. Tiu RA, et al. Laryngoscope Investig Otolaryngol. 2022 Sep 5;7(5):1491-1498. doi: 10.1002/lio2.912. eCollection 2022 Oct. Laryngoscope Investig Otolaryngol. 2022. PMID: 36258878 Free PMC article.
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
Wang ES, Montesinos P, Minden MD, Lee JH, Heuser M, Naoe T, Chou WC, Laribi K, Esteve J, Altman JK, Havelange V, Watson AM, Gambacorti-Passerini C, Patkowska E, Liu S, Wu R, Philipose N, Hill JE, Gill SC, Rich ES, Tiu RV. Wang ES, et al. Among authors: tiu rv. Blood. 2022 Oct 27;140(17):1845-1857. doi: 10.1182/blood.2021014586. Blood. 2022. PMID: 35917453 Free PMC article. Clinical Trial.
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia.
Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, McCloskey J, Smith CC, Schiller G, Bradley T, Tiu RV, Naqvi K, Dail M, Brackman D, Siddani S, Wang J, Chyla B, Lee P, Altman JK. Daver N, et al. Among authors: tiu rv. J Clin Oncol. 2022 Dec 10;40(35):4048-4059. doi: 10.1200/JCO.22.00602. Epub 2022 Jul 18. J Clin Oncol. 2022. PMID: 35849791 Free PMC article. Clinical Trial.
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
Perl AE, Hosono N, Montesinos P, Podoltsev N, Martinelli G, Panoskaltsis N, Recher C, Smith CC, Levis MJ, Strickland S, Röllig C, Groß-Langenhoff M, Chou WC, Lee JH, Yokoyama H, Hasabou N, Lu Q, Tiu RV, Altman JK. Perl AE, et al. Among authors: tiu rv. Blood Cancer J. 2022 May 30;12(5):84. doi: 10.1038/s41408-022-00677-7. Blood Cancer J. 2022. PMID: 35637252 Free PMC article.
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Récher C, Yoon SS, Hosono N, Onozawa M, Chiba S, Kim HJ, Hasabou N, Lu Q, Tiu R, Levis MJ. Perl AE, et al. Among authors: tiu r. Blood. 2022 Jun 9;139(23):3366-3375. doi: 10.1182/blood.2021011583. Blood. 2022. PMID: 35081255 Free PMC article. Clinical Trial.
135 results